AS
Ascendis Pharma
ASND · NASDAQ
$270.09 +2.24% (+$5.93)
1M +5.66%
Market Cap 14.4B €
P/E Ratio 19.08x
Div. Yield -
ROE 190.44%
Bulios Fair Price
$183.38
32.1% downside
Current Price
$270.09
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ASND is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
19 /100
Expensive P/FCF 42.81x
P/S 13.68x
P/B 10.05x
Growth
100 /100
Growing Rev. growth 138.21%
FCF growth N/A
Book val. growth N/A
Profitability
83 /100
Strong Net margin 71.69%
Op. margin 10.38%
FCF margin 31.95%
Quality
91 /100
Excellent ROE 190.44%
ROA 33.08%
Asset turnover 0.46x
Debt
81 /100
Low Current ratio 2.99x
Int. coverage 0.37x
Net debt/EBITDA -4.63x
Stability
42 /100
Moderate Rev. volatility 208.39%
EPS volatility 14.08%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ASND
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jan Moller Mikkelsen
Employees
1,189
Headquarters
Hellerup
Upcoming events
11 NOV
Earnings
Upcoming earnings report